 |
 |
Brian, I agree completely that requip is not a breakthrough. It is a rather small step but an important one. They have made a drug that act on only one receptor site, like at least 2 others (one marketed in the US.). I don't think that professionals really believe the advertising anyway. EVERY drug that comes on the market is a MAJOR BREAKTHROUGH. It likely will postpone dyskinesias and that is clearly a positive. Charlie Brian Collins wrote: > It seems to me that almost everyone is missing the point about this > non-event. I will try again to convey the points which are really > irritating me. > > 1/ SmithKline Beecham have made NO major breakthrough. > > 2 SmithKline Beecham have simply re-stated what we have all known for the > past 5 years: that the Dopamine Agonists from Permax on are capable of > acting like dopamine to the nervous system, without increasing the > risk of dyskinesia. (My tablet strategy has been based on this fact > for the last 5 years. > > 3/ I admit to a grudging respect at SKB's nerve at wrapping the package > so that it fools (apparently) just about everyone at the conference. > > 4/ Alternatively (and very scary) - it may be that SKB really believed > the results of their 'research'. Could this be true? . The bottom > line seems to be that SKB have fooled a convention-hall full of > specialists, or they have fooled a convention-hall full of specialists > AND themselves. (And if this sounds like the famous old question > 'Have you stopped beating your wife?' - GOOD!) > -- > Brian Collins <[log in to unmask]> -- ****************************************************************************************** Charles T. Meyer, M.D. Middleton (Madison), Wisconsin [log in to unmask] ******************************************************************************************